 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Smith & Nephew plc (SNN) develops, manufactures, and sells medical devices worldwide.
The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue.
In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints.
Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. Additionally, it offers meniscal repair system. It primarily serves the providers of medical and surgical treatments and services.
On July 31st, Smith & Nephew Snats reported 4th Quarter December 2014 earnings of $0.51 per share on revenue of $1.2 billion. The consensus earnings estimate was $0.51 per share on revenue of $1.3 billion. Revenue grew 6.3% on a year-over-year basis.
Shares have formed a bullish "cup and handle" and are expected to move higher from this formation.
Entry Point: $46.00
Stop Loss: $43.70
Trading Range: $32.215 to $47.05
Target Price: $50.60
SNN closed at $47.40
